1. The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma
- Author
-
Mackay, T.M., Smits, F.J., Roos, D., Bonsing, B.A., Bosscha, K., Busch, O.R., Creemers, G.J., Dam, R.M. van, Eijck, C.H.J. van, Gerhards, M.F., Groot, J.W.B. de, Koerkamp, B.G., Mohammad, N.H., Harst, E. van der, Hingh, I.H.J.T. de, Homs, M.Y.V., Kazemier, G., Liem, M.S.L., Meijer, V.E. de, Molenaar, I.Q., Nieuwenhuijs, V.B., Santvoort, H.C. van, Schelling, G.P. van der, Stommel, M.W.J., Tije, A.J. ten, Vos-Geelen, J. de, Wit, F., Wilmink, J.W., Laarhoven, H.W.M. van, Besselink, M.G., Dutch Pancreatic Canc Grp, Graduate School, AGEM - Digestive immunity, AGEM - Endocrinology, metabolism and nutrition, AGEM - Re-generation and cancer of the digestive system, CCA - Cancer Treatment and Quality of Life, Surgery, Oncology, CCA - Cancer Treatment and quality of life, Medical Oncology, Groningen Institute for Organ Transplantation (GIOT), Center for Liver, Digestive and Metabolic Diseases (CLDM), RS: NUTRIM - R2 - Liver and digestive health, MUMC+: MA Heelkunde (9), Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), and RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy
- Subjects
Male ,SURGERY ,medicine.medical_treatment ,INTERNATIONAL STUDY-GROUP ,030230 surgery ,SURGICAL COMPLICATIONS ,Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14] ,0302 clinical medicine ,Risk Factors ,Odds Ratio ,Hospital Mortality ,POSTOPERATIVE COMPLICATIONS ,Netherlands ,Gastroenterology ,Age Factors ,Middle Aged ,Pancreaticoduodenectomy ,OPEN-LABEL ,CANCER ,Pancreatic fistula ,Chemotherapy, Adjuvant ,030220 oncology & carcinogenesis ,PANCREATICODUODENECTOMY ,Female ,medicine.drug ,Carcinoma, Pancreatic Ductal ,medicine.medical_specialty ,Hospitals, Low-Volume ,03 medical and health sciences ,Pancreatectomy ,Pancreatic cancer ,medicine ,Journal Article ,Humans ,Aged ,Retrospective Studies ,Chemotherapy ,Performance status ,Hepatology ,business.industry ,MORTALITY ,Postoperative complication ,Odds ratio ,medicine.disease ,Gemcitabine ,Surgery ,Pancreatic Neoplasms ,Logistic Models ,DEFINITION ,GEMCITABINE ,Neoplasm Grading ,business - Abstract
Contains fulltext : 226028.pdf (Publisher’s version ) (Closed access) BACKGROUND: The relation between type of postoperative complication and not receiving chemotherapy after resection of pancreatic ductal adenocarcinoma (PDAC) is unclear. The aim was to investigate which patient factors and postoperative complications were associated with not receiving adjuvant chemotherapy. METHODS: Patients who underwent resection (2014-2017) for PDAC were identified from the nationwide mandatory Dutch Pancreatic Cancer Audit. The association between patient-, tumor-, center-, treatment characteristics, and the risk of not receiving adjuvant chemotherapy was analyzed with multivariable logistic regression. RESULTS: Overall, of 1306 patients, 24% (n = 312) developed postoperative Clavien Dindo ≥3 complications. In-hospital mortality was 3.5% (n = 46). Some 433 patients (33%) did not receive adjuvant chemotherapy. Independent predictors (all p
- Published
- 2020